Reported by Scientific American •
30 Mainstream framing provisional
Why this rating? · 1 signal

Signals flagged in the original

  • headline asserts a conclusion / scare-quotes

Provisional estimate — refines shortly Full breakdown ↓

Moderna and Merck report trial results on mRNA therapy for melanoma

Moderna and Merck have reported findings from a clinical trial that suggest their mRNA therapy can significantly lower the chances of melanoma recurrence. The treatment works by enhancing the immune system's ability to attack melanoma cells.

Companies
Moderna Merck

Our neutral summary

Moderna and Merck have reported findings from a clinical trial that suggest their mRNA therapy can significantly lower the chances of melanoma recurrence. The treatment works by enhancing the immune system's ability to attack melanoma cells.

Read the full story at Scientific American

The reporting belongs to Scientific American; we don't reproduce it. You can compare how outlets framed this story below.

Annotating as

Notes are private: only you can see them.

No note attached

of yours on this article.

Language Analysis

Loaded-language score 30/100
wirepublicmainstream flavoredpartisanadvocacy
Inflammatory language 10/100
Sentiment +50/100

Loaded Language Removed

  • ✕ headline asserts a conclusion / scare-quotes

Original vs. Neutral

Original Headline

Moderna and Merck announce ‘landmark’ trial showing mRNA therapy significantly cuts odds of recurrent skin cancer

Neutral Headline

Moderna and Merck report trial results on mRNA therapy for melanoma